Core Viewpoint - Ginkgo Bioworks has launched a cost-effective, high-throughput ADME profiling service aimed at accelerating small molecule drug discovery, with a focus on providing model-ready datasets and competitive pricing compared to international vendors [1][2][3] Company Overview - Ginkgo Bioworks is positioned as a leading platform for cell programming and biosecurity, offering integrated laboratory automation and large lab datasets to support AI model development [4] New Service Features - The new ADME profiling service is designed to enhance the drug development pipeline for small molecules, providing early access to rich ADME data that empowers researchers to prioritize candidates and train predictive models efficiently [2][6] - Key features include automated workflows, cost-effective pricing with a price match guarantee against international vendors, and rapid turnaround times to align with modern discovery cycles [6][3] Leadership Statement - Jason Kelly, co-founder and CEO of Ginkgo Bioworks, expressed confidence that the new ADME service will be transformative for drug discovery, emphasizing the company's ability to offer competitive pricing and quality through automation and scale [3]

Core Insights - Ginkgo Bioworks Holdings, Inc. plans to host a presentation and Q&A session to review its business performance for Q1 2025 on May 6, 2025, at 5:30 p.m. ET [1] - The presentation details and a replay will be available on Ginkgo's investor relations website [2] - Ginkgo Bioworks is recognized as a leading platform for cell programming, offering services across various markets including food, agriculture, pharmaceuticals, and chemicals [3] Company Overview - Ginkgo Bioworks provides flexible, end-to-end services to address challenges in diverse sectors [3] - The company is also focused on biosecurity, developing infrastructure and technologies to manage biological threats [3] - For further information, Ginkgo maintains an active presence on social media and its websites [3]